GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Beijing Strong Biotechnologies Inc (SZSE:300406) » Definitions » Capex-to-Operating-Cash-Flow

Beijing Strong Biotechnologies (SZSE:300406) Capex-to-Operating-Cash-Flow : 2.24 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Beijing Strong Biotechnologies Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Beijing Strong Biotechnologies's Capital Expenditure for the three months ended in Mar. 2024 was ¥-39.39 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was ¥17.55 Mil.

Hence, Beijing Strong Biotechnologies's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2024 was 2.24.


Beijing Strong Biotechnologies Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Beijing Strong Biotechnologies's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Strong Biotechnologies Capex-to-Operating-Cash-Flow Chart

Beijing Strong Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.14 0.19 0.24 0.25

Beijing Strong Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.48 0.28 0.16 0.18 2.24

Competitive Comparison of Beijing Strong Biotechnologies's Capex-to-Operating-Cash-Flow

For the Diagnostics & Research subindustry, Beijing Strong Biotechnologies's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Strong Biotechnologies's Capex-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Beijing Strong Biotechnologies's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Beijing Strong Biotechnologies's Capex-to-Operating-Cash-Flow falls into.



Beijing Strong Biotechnologies Capex-to-Operating-Cash-Flow Calculation

Beijing Strong Biotechnologies's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-148.032) / 585.093
=0.25

Beijing Strong Biotechnologies's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-39.385) / 17.551
=2.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Strong Biotechnologies  (SZSE:300406) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Beijing Strong Biotechnologies Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Beijing Strong Biotechnologies's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Strong Biotechnologies (SZSE:300406) Business Description

Traded in Other Exchanges
N/A
Address
No. 15 Hua Yuan Dong Lu, 5th Floor, Kuang Yi Building, Haidian District, Beijing, CHN, 100191
Beijing Strong Biotechnologies Inc is a China-based provider of in-vitro (IVD) diagnostics products and service. The company is engaged in the research, development, production, and sale of IVD products. It also provides diversified clinical diagnosis solutions to customers. Its products include clinical biochemistry testing, coagulation testing, blood typing, serology and automated blood grouping analyzer. The firm has established a clinical biochemistry platform of the enzymatic method (including enzymatic cycling method), immunoturbidimetric method, and latex immunoturbidimetric method.
Executives
Shuang He Executives
Luo Ai Ping Director
Directors, executives
Liu Wei Executives
Zhou Ming Executives
Zhuang Xian Min Directors, executives
Zhang Yi Executives
Liu Xi Directors, executives
Sun Xiao Lin Director
Yu Jian Ping Executives

Beijing Strong Biotechnologies (SZSE:300406) Headlines

No Headlines